Pain Treatment Developer Centrexion Reveals IPO Plans
October 19 2018 - 7:03PM
Dow Jones News
By Christopher Zinsli
Centrexion Therapeutics Corp., a pain treatment developer
founded by the former leaders of Pfizer Inc. and Celgene Corp., on
Friday disclosed plans to go public.
The Boston-based company said the proceeds from its planned
initial public offering would fund clinical trials of a series of
product candidates. The company's most advanced candidate is a
potential treatment for knee pain.
Centrexion said it had an accumulated deficit of $125.7 million
as of Sept. 30.
Former Pfizer Chief Executive Jeffrey Kindler is CEO of
Centrexion, and former Celgene Corp. Chief Executive Sol Barer is
the company's chairman.
Centrexion in January announced a $67 million Series D funding
round. New Enterprise Associates led that round and is a
significant shareholder, according to the company's IPO prospectus.
Other significant owners include InterWest Partners and Quan
Capital.
The company intends to secure a listing on the Nasdaq under the
symbol CNTX. BofA Merrill Lynch, Leerink Partners and Evercore ISI
are leading the offering.
(END) Dow Jones Newswires
October 19, 2018 18:48 ET (22:48 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024